Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "management"

1351 News Found

AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease
People | March 26, 2024

AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease

Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology


Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India
Drug Approval | March 23, 2024

Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India

Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI


Abbott India appointed Swati Dalal as MD
People | March 16, 2024

Abbott India appointed Swati Dalal as MD

Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager


Nectar Lifesciences’ suo moto clarification on a news item
News | March 07, 2024

Nectar Lifesciences’ suo moto clarification on a news item

Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs


Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer
People | March 07, 2024

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis


Dr. Lal PathLabs CEO Bharath Uppilliappan steps down
People | March 07, 2024

Dr. Lal PathLabs CEO Bharath Uppilliappan steps down

Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO


Amita Sharma redesignated As COO- API at Morepen Lab
People | March 07, 2024

Amita Sharma redesignated As COO- API at Morepen Lab

Sharma joined the Morepen Lab in 2004


Suven announces merger of Cohance Lifesciences
News | March 01, 2024

Suven announces merger of Cohance Lifesciences

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals